Search Results - "Minton, S E"

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer by Munster, P N, Thurn, K T, Thomas, S, Raha, P, Lacevic, M, Miller, A, Melisko, M, Ismail-Khan, R, Rugo, H, Moasser, M, Minton, S E

“…Background: Histone deacetylases (HDACs) are crucial components of the oestrogen receptor (ER) transcriptional complex. Preclinically, HDAC inhibitors can…”
Get full text

Chemoprevention of breast cancer in the older patient by Minton, S E

“…Age is the most important risk factor for the development of breast cancer. The risk of breast cancer continues to increase in American women until the age of…”
Get more information

Severe Lhermitte-Duclos disease with unique germline mutation of PTEN by Sutphen, Rebecca, Diamond, Theresa M., Minton, Susan E., Peacocke, Monica, Tsou, Hui C., Root, Allen W.

“…Germline mutations in the PTEN gene have recently been identified in some individuals with Cowden disease (CD), Lhermitte‐Duclos disease (LDD), and…”
Get full text

A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors by Minton, S. E., LoRusso, P., Lockhart, A. C., Saif, M., Krishnamurthi, S. S., Pickett-Gies, C. A., Wang, Y., Guan, S., Roben, E., Stein, M. N.

“…Abstract only…”
Get full text

Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy by Munster, P. N., Lacevic, M., Thomas, S., Christian, C., Ismail-Khan, R., Melisko, M., Rugo, H., Minton, S. E.

“…Abstract only 1075 Background: Modulation of estrogen receptor signaling is one of the most successful modalities in the treatment of estrogen receptor (ER)…”
Get full text

Abstract P2-14-04: A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer by Means-Powell, JA, Minton, SE, Mayer, IA, Abramson, VG, Ismail-Khan, R, Arteaga, CL, Ayers, DA, Sanders, MS, Lush, RM, Miele, L

“…Abstract Background: RO4929097 is a potent and oral selective inhibitor of γ-secretase (GSI), producing inhibitory activity of Notch 1–4 signaling in tumor…”
Get full text